You are here

  • Home
  • Archive
  • Volume 11, Issue 2
  • Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL

 

Online download statistics by month:

Online download statistics by month: February 2023 to January 2026

AbstractFullPdf
Feb 202332132379
Mar 2023403408125
Apr 202334534877
May 202338939460
Jun 202321621749
Jul 202320921075
Aug 202319419543
Sep 202318718730
Oct 202320720849
Nov 202324024346
Dec 202317518064
Jan 2024656738
Feb 202410610722
Mar 202427227764
Apr 202418118969
May 20249810045
Jun 202414714650
Jul 202411711860
Aug 2024737342
Sep 2024899334
Oct 202413213246
Nov 202413914145
Dec 202414915140
Jan 202513813842
Feb 202520721059
Mar 202517617638
Apr 202514114241
May 202510711243
Jun 2025545623
Jul 2025110
Sep 2025110
Dec 2025550
Jan 2026001
Total528453481499